Federico Marchesi1, Francesco Tartamella2, Giuseppina De Sario2, Clarissa Forlini2, Alberta Caleffi3, Matteo Riccò4, Francesco Di Mario5. 1. Unit of Clinical Surgery, Department of Medicine and Surgery, Parma University Hospital, Via Gramsci 14, 43126, Parma, Italy. fede53@lycos.com. 2. Unit of Clinical Surgery, Department of Medicine and Surgery, Parma University Hospital, Via Gramsci 14, 43126, Parma, Italy. 3. Diagnostic Blood Chemistry Unit, Parma NHS-University Hospital, Via Gramsci, 14, 43126, Parma, Italy. 4. Workplace Prevention and Safety Unit, Health Service Provincial Agency of the Province of Trento, Prevention Department, Via Verona C/O Health Service Center, 38123, Trento, Italy. 5. Department of Clinical and Experimental Medicine, University of Parma, School of Medicine, Via Gramsci 14, 43126, Parma, Italy.
Abstract
BACKGROUND: Morpho-functional modifications of the gastric remnant after Roux-en-Y gastric bypass (RYGB) have not been completely defined, due to its inaccessibility for bioptic mapping. The aim of the study is to evaluate such modifications using Gastropanel®, a non-invasive blood test cross-checking four gastric biomarkers, able to provide a snapshot of mucosa conditions. SUBJECTS AND METHODS: Twenty-four women undergoing RYGB were prospectively enrolled. Gastropanel® parameters (pepsinogens, Gastrin-17 and immunoglobulins against Helicobacter pylori), biometrical/clinical data were collected preoperatively and at 6-months follow-up. RESULTS: All parameters showed significant reduction (p < 0.05). Pepsinogen I reduction correlated with BMI percent decrease. CONCLUSIONS: The exclusion of food transit is responsible for significant drop in gastric output, hardly representing a risk factor in the remnant carcinogenesis, being unexposed to alimentary carcinogenic agents.
BACKGROUND: Morpho-functional modifications of the gastric remnant after Roux-en-Y gastric bypass (RYGB) have not been completely defined, due to its inaccessibility for bioptic mapping. The aim of the study is to evaluate such modifications using Gastropanel®, a non-invasive blood test cross-checking four gastric biomarkers, able to provide a snapshot of mucosa conditions. SUBJECTS AND METHODS: Twenty-four women undergoing RYGB were prospectively enrolled. Gastropanel® parameters (pepsinogens, Gastrin-17 and immunoglobulins against Helicobacter pylori), biometrical/clinical data were collected preoperatively and at 6-months follow-up. RESULTS: All parameters showed significant reduction (p < 0.05). Pepsinogen I reduction correlated with BMI percent decrease. CONCLUSIONS: The exclusion of food transit is responsible for significant drop in gastric output, hardly representing a risk factor in the remnant carcinogenesis, being unexposed to alimentary carcinogenic agents.
Authors: P Malfertheiner; F Megraud; C A O'Morain; J P Gisbert; E J Kuipers; A T Axon; F Bazzoli; A Gasbarrini; J Atherton; D Y Graham; R Hunt; P Moayyedi; T Rokkas; M Rugge; M Selgrad; S Suerbaum; K Sugano; E M El-Omar Journal: Gut Date: 2016-10-05 Impact factor: 23.059
Authors: Adrian G McNicholl; Montserrat Forné; Jesus Barrio; Cristobal De la Coba; Begoña González; Robin Rivera; Maria Esteve; Fernando Fernandez-Bañares; Beatriz Madrigal; Beatriz Gras-Miralles; Angeles Perez-Aisa; Jose M Viver-Pi-Sunyer; Felipe Bory; Merce Rosinach; Carmen Loras; Carlos Esteban; Santos Santolaria; Fernando Gomollon; Julio Valle; Javier P Gisbert Journal: Eur J Gastroenterol Hepatol Date: 2014-09 Impact factor: 2.566